Glass House Brands (GLAS) Notes Payables (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Notes Payables of $38000.0 for Q1 2026, up 2.7% quarter-over-quarter from $37000.0 in Q4 2025.

Glass House Brands (GLAS) Notes Payables (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Notes Payables for 7 consecutive years, with $38000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Notes Payables changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $38000.0 (changed N/A YoY), while the FY2025 annual figure was $37000.0, down 99.52% from the prior year.
Notes Payables climbed to $38000.0 in Q1 2026 per GLAS's latest filing, from $37000.0 in the prior quarter.
Across five years, Notes Payables topped out at $9.5 million in Q2 2022 and bottomed at -$10.0 million in Q3 2022.
Historically, Notes Payables has averaged $2.5 million across 5 years, with a median of $48787.0 in 2023.
Annual changes were most pronounced in 2022 — Notes Payables sank 959.04% — and 2023, when it surged 18663.82%.
Glass House Brands' Notes Payables stood at $40237.0 in 2022, then soared by 18663.82% to $7.6 million in 2023, then rose by 1.25% to $7.6 million in 2024, then plunged by 99.52% to $37000.0 in 2025, then grew by 2.7% to $38000.0 in 2026.
Business Quant data shows GLAS's Notes Payables at $38000.0 in Q1 2026, $37000.0 in Q4 2025, and $36000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Glass House Brands	828.45 Mn	809.90 Mn	15.77 Mn

Download Data